Clinical Trials Logo

Clinical Trial Summary

Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly. Although, there are considerable ongoing efforts to develop a vaccine, vector control remains the only option for reducing dengue virus (DENV) transmission and disease burden. The recent emergence of Aedes-borne Zika (ZIKV) and Chikungunya viruses (CHIKV) highlight need for novel vector control tools. The goal of this project is to determine the efficacy of a spatial repellent (SR) product (active ingredient transfluthrin) for reducing contact between household residents and vector mosquitos and as a result reduce DENV, ZIKV, and/or other Aedes-borne virus transmission. Henceforth the investigators will designate the combined risk of Aedes-borne dengue, Chikungunya, Zika virus transmission by (DCZV). Spatial repellency is used here as a general term to refer to a range of insect behaviors caused by airborne chemicals that reduce contact between people and disease vectors. This can include movement away from a chemical stimulus, and interference with host detection (attraction-inhibition) and/or feeding response.


Clinical Trial Description

Protection provided by this product will be measured using entomological and virological approaches, comparing entomological indices will be measured through standard household monitoring of Aedes aegypti population densities, while DCZV transmission will be measured through door-to-door surveillance for active dengue disease and through serological monitoring for DCZV exposure in a randomized cluster trial. The investigators will establish a cohort of 3,400 persons, primarily children 2-12 years of age and adults who have not been previously infected with DCZV who will provide annual blood samples when they are healthy (longitudinal cohort), whereas in the same clusters the investigators expect to monitor up to 27,500 residents for active dengue disease (febrile surveillance cohort). The cohort will be monitored for a period of 2 years. The use of spatial repellents has never been tested on a large scale to reduce disease and could change vector control practices worldwide, reducing the amount of chemical insecticides applied and also prevent the development of insecticide resistance. The investigators plan to implement a short questionnaire to determine levels of acceptability and perceived efficacy amongst participating households. The project will be carried out in the Amazonia City of Iquitos, Peru, which has a well-established infrastructure for studying urban dengue fever. The study will generate rigorous evidence, documenting and evaluating the impact of SR products on human infection rates, to be considered and used by academia, industry and public health key stakeholders at the global, regional, national and/or local level and drive efforts to acquire full recommendation of SR products for inclusion in disease control programs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03553277
Study type Interventional
Source University of Notre Dame
Contact
Status Completed
Phase N/A
Start date June 2015
Completion date March 2019

See also
  Status Clinical Trial Phase
Completed NCT01868399 - Pilot Survey of Dengue Fever in Solomon Islands N/A
Recruiting NCT05452447 - Spatial Repellents for Aedes-borne Virus Control in Sri Lanka N/A
Completed NCT03210363 - Sero-epidemiology of Priority Arboviruses in French Guiana N/A
Recruiting NCT03552094 - World Mosquito Program Noumea - Human Sample Component
Completed NCT00116766 - Field Evaluation of Plant-based Mosquito Control Phase 2
Recruiting NCT04615364 - Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Recruiting NCT04954352 - Human Epidemiology of Newly Identified Arboviruses
Completed NCT06268691 - Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating N/A
Recruiting NCT04619823 - Virological and Immunological Determinants of Arbovirus Infection in New Caledonia N/A